Safety and immunogenicity of a new Neisseria meningitidis serogroup C- tetanus toxoid conjugate vaccine in healthy adults

Vaccine

Volumn 18, Issue 7-8, 1999, Pages 641-646

  Richmond, Peter ^a   Goldblatt, David ^a   Fusco, Peter C ^b   Fusco, Joan D S ^b   Heron, Iver ^b   Clark, Sarah ^c   Borrow, Ray ^c   Michon, Francis ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b North American Vaccine Inc   (United States)

^c WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

Avidity; Conjugate vaccine; Polysaccharide; Serogroup C meningococcus

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; MENINGOCOCCAL C TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MENINGOCOCCOSIS; MYALGIA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BACTERIAL CAPSULES; BACTERIAL VACCINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; T-LYMPHOCYTES; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0032709595     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00276-5     Document Type: Article

References (29)

1. Ramsay M., Collins M., Rush M., Kaczmarski E. The epidemiology of meningococcal disease in England and Wales 1996 and 1997. Eurosurveillance. 2:1997;74-76.
2. Kaczmarski E.B. Meningococcal disease in England and Wales: 1995. CDR Rev. 7:1997;R55-R59.
3. Whalen C.M., Hopckin J.C., Ryan A., Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: emergence of a virulent clone of Neisseria meningitidis. JAMA. 273:1995;390-394.
4. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:1970;417-420.
5. Mitchell L.A., Ochnio J.J., Glover C., Lee A.Y., Ho M.K.L., Bell A. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. J. Infect. Dis. 173:1996;1009-1013.
6. Taunay A.E., Galvao P.A., de Morais J.S., Gotschlich E.C., Feldman R.A. Disease prevention by meningococcal serogroup C polysaccharide vaccine in pre-school children: results after 11 months in Sao Paulo, Brazil (abstr.). Pediatr. Res. 8:1974;429A.
7. Macdonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. JAMA. 280:1998;1685-1689.
8. Granoff D.M., Gupta R.K., Belshe R.B., Anderson E.L. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis. 178:1998;870-874.
9. Goldblatt D., Pinto Vas A.R.J.P.M., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunisation. J. Infect. Dis. 177:1998;1112-1115.
10. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1998;1614-1621.
11. Fairley C.K., Begg N., Borrow R., Fox A.J., Jones D.M., Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1996;1360-1363.
12. Leach A., Twumasi P.A., Kumah S., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:1997;200-204.
13. Beuvery E.C., Roy R., Kanhai V., Jennings H.J. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein. Dev. Biol. Stand. 65:1986;197-204.
14. Jennings H.J., Lugowski C. Immunochemistry of groups A, B and C meningococcal polysaccharide antigens. J. Immunol. 127:1981;1011-1018.
15. Gheesling L.L., Carlone G.M., Pais L.B., et al. Multicenter comparison of Neisseria meningitidis serogroup C anticapsular polysaccharide antibody levels measured by standardised enzyme-linked immunosorbent assay. J. Clin. Microbiol. 32:1994;1475-1482.
16. Holder P.K., Maslanka S.E., Pais L.B., Dykes J., Plikaytis B.D., Carlone G.M. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin. Diag. Lab. Immunol. 2:1995;132-137.
17. Kristiansen M., Aggerbeck H., Heron I. Improved ELISA for determination of anti-diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS. 105:1997;843-853.
18. Anderson E.L., Bowers T., Mink C.M., et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62:1994;3391-3395.
19. Goldblatt D. Simple solid phase assays of avidity. Turner M.W., Johnson A.P. Immunochemistry 2: a practical approach. 1997;31-51 IRL Press at Oxford University Press, Oxford.
20. Constantino P., Viti S., Podda M.A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 10:1992;691-698.
21. Goldschneider I., Gotschlich E.C., Artenstein M.S. Humoral immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1969;1307-1326.
22. Maslanka S.E., Tappero J.W., Plikaytis B.D., et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect. Immun. 66:1998;2453-2459.
23. Arakere G., Frasch C.E. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect. Immun. 59:1991;4349-4356.
24. Glode M.P., Lewin E.B., Sutton A., Le C T., Gotschlich E.C., Robbins J.B. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl positive and O-acetyl negative variants and Eschericia coli K92 in adult volunteers. J. Infect. Dis. 139:1979;52-59.
25. 135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl negative and O-acetyl positive serogroup C polysaccharides. Pediatrics. 76:1985;91-96.
26. Zangmill K.M., Stout R.W., Carlone G.M., Pais L., Harekeh H., Mitchell S., et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J. Infect. Dis. 169:1994;847-852.
27. King W.J., MacDonald N.E., Wells G., et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J. Pediatr. 128:1996;196-201.
28. Lieberman J.M., Chiu S.S., Wong V.K., Partridge S., Chang S., Chiu C., et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA. 275:1996;1499-1503.
29. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA. 267:1992;1489-1494.